Autor: Firma Biognosys

Biognosys and Bruker Collaborate to Support Ion Mobility on timsTOF Pro with Spectronaut

17. September 201917. September 2019 Firma BiognosysKooperationen / Fusionenbruker, dda, dia, diaPASEF, ion mobility, lcms, PASEF, proteomics, Spectronaut, timsTOF Pro

Researchers will soon be able to directly measure and quantify thousands of proteins using Bruker’s (Nasdaq: BRKR) new ion mobility-based mass spectrometer and the corresponding data analysis software Spectronaut, developed by Biognosys; the Swiss next-generation proteomics company. The performance of Mehr

Biognosys Completes Series G Financing Round to Accelerate its Expansion into Clinical Trials Market

8. August 2019 Firma BiognosysBiotechnikbiomarkers, Biotech, biotechnology, Clinical Trials, contract research, drug development, drug discovery, lcms, Mass Spectrometry, protein, proteomics, research and development, science, shareholders, technology

Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company Mehr